A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients-Reference-Cited by-同舟云学术

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

Published:2019-08 Issue:4-5 Volume:46 Page:362-371
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Cortellini Alessio^ORCID,Buti Sebastiano^ORCID,Agostinelli Veronica,Bersanelli Melissa

Funder

Boehringer Ingelheim

Sanofi

Pfizer

Meso Scale Diagnostics

Novartis

British Microcirculation Society

Ipsen Biopharmaceuticals

Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference60 articles.

1. Association between treatment toxicity and outcomes in oncology clinical trials;Abola;Ann Oncol,2014

2. Clinical significance of skin toxicity due to EGFR-targeted therapies;Giovannini;J Oncol.,2009

3. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III Studies;Hurwitz;Oncologist,2013

4. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors;Rini;Clin Cancer Res,2011

5. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis;Wang;JAMA Oncol,2019

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors and SARS-CoV2 infection;International Immunopharmacology;2024-08

2. High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial;PLOS ONE;2024-07-05

3. Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness;Frontiers in Oncology;2024-06-26

4. Endocrine health in survivors of adult-onset cancer;The Lancet Diabetes & Endocrinology;2024-05

5. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30